Journal Guide

Authors who wish to submit reviews to the journal are requested to submit a short synopsis of their chosen subject to the Editor. Further information regarding the submission of manuscripts and guidelines for the preparation of the manuscripts can be found in the Guide for Authors.

Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of conditions associated with hematologic malignancy.

Current Opinion in HIV and AIDS offers full and complete coverage enabling clinicians and researchers to keep up-to-date with the vast amount of information published in the field. Insightful editorials and on-the-mark invited reviews bring readers up-to-speed on key subjects such as the T-cell in HIV infection and disease, reservoirs, host factors, HIV vaccines, antiretroviral therapy and clinical trial design.Website: www.co-hivandaids.com.

Current Opinion in Hematology is an easy-to-digest bimonthly journal covering the most interesting and important advances in the field of hematology. Its hand-picked selection of editors ensure the highest quality selection of unbiased review articles on themes from nine key subject areas, including myeloid biology, Vascular biology, hematopoiesis and erythroid system and its diseases. Each issue also contains a Current World Literature section, offering a thorough bibliography of papers selected from hundreds of top journals in the field.

Devoted exclusively to the study of the molecular biology, biochemistry, immunology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, and new cytokines, Cytokine provides comprehensive coverage of cytokines and their receptors, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors.Special issues:Suggestions for special issue topics and guest editors can be sent to Paul Taylor, p.taylor@elsevier.comBenefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT).Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, physicians, and regulatory experts involved in cell processing and therapy.The journal's scope includes research in:Stem cell processing and transplantationCell-based therapies of malignant and non-malignant blood diseasesCancerStem cell plasticityAutoimmune diseasesImmunotherapyCongenital disordersNovel molecular therapiesGene therapyMicrovesicle biology and therapeutic application

Zielsetzung der Zeitschrift
Der Onkologe behandelt praxisnah Fragen zu Diagnose und Therapie onkologischer Er­krankungen. Besondere Berücksichtigung finden dabei die onkologisch arbeitenden Fachrichtungen Innere Medizin, Radiologie und Chirurgie. Die interdisziplinäre Zeitschrift richtet sich an onkologisch tätige Ärzte in Praxis und Klinik.
Umfassende Übersichtsarbeiten zu einem aktuellen Schwerpunktthema sind das Kernstück jeder Ausgabe. Im Mittelpunkt steht dabei evidenzbasiertes Wissen zu Diagnostik und Therapie mit hoher Relevanz für die tägliche Arbeit – der Leser erhält konkrete Handlungsempfehlungen. Die Schwerpunktthemen werden von einem unabhängigen Herausgeberboard geplant. Ausgewiesene Experten verfassen anschließend die aufeinander abgestimmten Beiträge.
Beiträge der Rubrik „CME Zertifizierte Fortbildung“ bieten gesicherte Ergebnisse wissenschaftlicher Forschung und machen ärztliche Erfahrung für die tägliche Praxis nutzbar. Nach Lektüre der Beiträge kann der

European Journal of Haematology is an international journal for communication of basic and clinical research in haematology. The journal welcomes manuscripts on molecular, cellular and clinical research on diseases of the blood, vascular and lymphatic tissue, and on basic molecular and cellular research related to normal development and function of the blood, vascular and lymphatic tissue. The journal also welcomes reviews on clinical haematology and basic research, case reports, and clinical pictures.

Initial review of manuscripts averages under 4 weeksArticles published online from 5 days after acceptanceUnrivalled access to 10 million healthcare professionals through ScienceDirectOver 280,000 article downloads in 2012Impact factor of 2.905 (© Thomson Reuters Journal Citation Reports 2012)Experimental Hematology publishes original research reports (regular and fast-track submissions), reviews, perspectives, letters to the editor, and abstracts of the annual meeting of ISEH - Society for Hematology and Stem Cells. We welcome manuscripts describing basic in vitro and in vivo research centered on normal and malignant hematopoiesis as well as non-malignant hematologic diseases. Submissions focused on non-hematopoietic stem cells (e.g. mesenchymal stem cells, embryonic stem cells and induced pluripotent stems) with potential relevance to hematopoiesis are also welcome, as are studies involving experimental or early phase clinical cell transplantation. Studies employing genomic and systems biology approaches to the study of normal and malignant hematopoiesis are strongly encouraged, as are those employing model organisms.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Experimental Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology with emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.Experimental Hematology & Oncology aims to publish original work, hypothesis, commentaries and timely reviews in the closely related fields of hematology and oncology.With open access, rapid turnaround time from submission to publication and online live comments from readers, Experimental Hematology & Oncology will strive to be the hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the field of hematology and oncology.

Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recommendations on publication ethics policies for medical journals.Haematologica was founded in 1920 by Adolfo Ferrata, and in 2005 merged with The Hematology Journal. Haematologica is the Official Organ of the following scientific societies.

Haemophilia is an international journal dedicated to the exchange of information regarding the comprehensive care of haemophilia. The Journal contains review articles, original scientific papers and case reports related to haemophilia care, with frequent supplements. Subjects covered include: